Purpose of Review

Despite widespread targeting of cardiovascular risk factors, many patients continue to experience clinical events. This residual risk has stimulated efforts to develop novel therapeutic approaches to target additional factors underscoring cardiovascular disease. This review aimed to summarize existing evidence supporting targeting of Lp(a) as a novel cardioprotective strategy.

Recent Findings

Increasing evidence has implicated lipoprotein (a) [Lp(a)] in the pathogenesis of both atherosclerotic and calcific aortic valve disease. Therapeutic advances have produced novel agents that selectively lower Lp(a) levels, which have now progressed to evaluate their impact on cardiovascular events in large clinical outcome trials.

Summary

Evidence continues to accumulate suggesting that targeting Lp(a) may be effective in reducing cardiovascular risk. With advances in Lp(a) targeted therapeutics, clinical trials now have the opportunity to determine whether this strategy will be effective for high-risk patients.

中文翻译：

---

风险更高的脂质：脂蛋白 (a) 的地平线是什么？是否应该对所有人进行 Lp(a) 筛查？

审查目的

尽管广泛针对心血管危险因素，但许多患者继续经历临床事件。这种残余风险促使人们努力开发新的治疗方法，以针对导致心血管疾病的其他因素。本综述旨在总结支持将 Lp(a) 靶向作为一种新型心脏保护策略的现有证据。

最近的发现

越来越多的证据表明脂蛋白 (a) [Lp(a)] 与动脉粥样硬化和钙化性主动脉瓣疾病的发病机制有关。治疗进展产生了选择性降低 Lp(a) 水平的新型药物，现在已在大型临床结果试验中评估其对心血管事件的影响。

概括

越来越多的证据表明，靶向 Lp(a) 可能有效降低心血管风险。随着 Lp(a) 靶向治疗的进步，临床试验现在有机会确定该策略是否对高危患者有效。